115 related articles for article (PubMed ID: 18088489)
1. [Analysis on prognosis and correlative factors of acute nonlymphocytic leukemia].
Liu CY; Fu R; Liu WH; Cheng YQ; Song WX; DU LJ; Ruan EB; Zhang LT; Wang XM; Liang Y; Wang GJ; Qu W; Song J; Zhang RL; Guan J; Li LJ; Song Y; Gao S; Liu H; Jiang HJ; Wang J; Zou P; Shao ZH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1300-4. PubMed ID: 18088489
[TBL] [Abstract][Full Text] [Related]
2. High-dose cytosine arabinoside and L-asparaginase therapy for poor-risk adult acute nonlymphocytic leukemia. A retrospective study.
Evans C; Winkelstein A; Rosenfeld CS; Zeigler ZR; Shadduck RK
Cancer; 1990 Jun; 65(12):2624-30. PubMed ID: 2340464
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
[TBL] [Abstract][Full Text] [Related]
4. [Clinical study on combination of homoharringtonine, Ara-C and idarubicin induction for treatment of newly diagnosed acute myeloid leukemia patients].
Qin TJ; Xu ZF; Fang LW; Zhang HL; Zhang Y; Wang JZ; Pan LJ; Hu NB; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1277-82. PubMed ID: 22040988
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia].
Bian SG; Hao YS; Wang ZC
Zhonghua Nei Ke Za Zhi; 1990 Jan; 29(1):22-5, 60. PubMed ID: 2401166
[TBL] [Abstract][Full Text] [Related]
6. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
[TBL] [Abstract][Full Text] [Related]
7. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
8. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
9. Curative effect of harringtonine semisynthetic harringtonine and HOAP on nonlymphocytic leukemias. Analysis of 304 cases.
Zhang ZY; Hou CH; Zhu YF; You XY; Li JL; Fu Z
Chin Med J (Engl); 1987 Jul; 100(7):565-8. PubMed ID: 3123163
[No Abstract] [Full Text] [Related]
10. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
Parovichnikova EN; Loukianova IA; Troitskaya VV; Drokov MY; Lobaova TI; Kuzmina LA; Sokolov AN; Kokhno AV; Fidarova ZT; Baskhaeva GA; Gavrilina OA; Vasilyeva VA; Obukhova TN; Kuznetsova SA; Sudarikov AB; Dvirnik VN; Galtseva IV; Davidiva JO; Kulikov SM; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):14-22. PubMed ID: 30701918
[TBL] [Abstract][Full Text] [Related]
11. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
[TBL] [Abstract][Full Text] [Related]
12. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
13. [Treatment results in childhood acute myeloblastic leukemia--a report of clinical trials of a past decade from the Japanese children's Cancer and Leukemia Study Group (CCLSG)].
Tsurusawa M; Katano N; Hirota T; Mimaya J; Horikoshi Y; Kawamura N; Yanai M; Kamitamari A; Tsuji Y; Fujimoto T
Rinsho Ketsueki; 1997 Jun; 38(6):505-12. PubMed ID: 9248326
[TBL] [Abstract][Full Text] [Related]
14. [Treatment results of acute nonlymphocytic leukemia in childhood--Kyushu Yamaguchi Children's Cancer Study Group].
Ikuno Y; Okamura J; Ishii E; Matuzaki A; Ueda K; Eguchi H; Inada H; Nibu K; Koga H; Miyazaki S
Rinsho Ketsueki; 1995 Apr; 36(4):325-33. PubMed ID: 7783338
[TBL] [Abstract][Full Text] [Related]
15. Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG).
Asou N; Adachi K; Tamura U; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Akiyama H; Tsubaki K; Saito K; Kuriyama K; Oh H; Kitano K; Miyawaki S; Takeyama U; Yamada O; Nishikawa K; Takahashi M; Matsuda S; Ohtake H; Ohno R
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S65-71. PubMed ID: 11587370
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients.
Wang S; Yuan X; Liu Y; Zhu K; Chen P; Yan H; Zhang D; Li X; Zeng H; Zhao X; Chen X; Zhou G; Cao S
J Transl Med; 2019 Mar; 17(1):101. PubMed ID: 30922329
[TBL] [Abstract][Full Text] [Related]
17. Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia.
Gu LF; Zhang WG; Wang FX; Cao XM; Chen YX; He AL; Liu J; Ma XR
J Cancer Res Clin Oncol; 2011 Jun; 137(6):997-1003. PubMed ID: 21152934
[TBL] [Abstract][Full Text] [Related]
18. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia.
Thomas X; Dombret H; Cordonnier C; Pigneux A; Gardin C; Guerci A; Vekhoff A; Sadoun A; Stamatoullas A; Fegueux N; Maloisel F; Cahn JY; Reman O; Gratecos N; Berthou C; Huguet F; Kotoucek P; Travade P; Buzyn A; de Revel T; Vilque JP; Naccache P; Chomienne C; Degos L; Fenaux P
Leukemia; 2000 Jun; 14(6):1006-13. PubMed ID: 10865965
[TBL] [Abstract][Full Text] [Related]
19. [Progress in the treatment of adult acute myeloid leukemia].
Ohno R
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1053-8. PubMed ID: 9239156
[TBL] [Abstract][Full Text] [Related]
20. Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).
Zhu HH; Jiang H; Jiang Q; Jia JS; Qin YZ; Huang XJ
Leuk Res; 2016 May; 44():40-4. PubMed ID: 26994850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
